Smith & Nephew PLC
LSE:SN

Watchlist Manager
Smith & Nephew PLC Logo
Smith & Nephew PLC
LSE:SN
Watchlist
Price: 986 GBX 0.94%
Market Cap: 8.6B GBX
Have any thoughts about
Smith & Nephew PLC?
Write Note

Smith & Nephew PLC
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Smith & Nephew PLC
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Smith & Nephew PLC
LSE:SN
Cash & Cash Equivalents
$568m
CAGR 3-Years
-26%
CAGR 5-Years
33%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cash & Cash Equivalents
$346.4m
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
11%
EKF Diagnostics Holdings PLC
LSE:EKF
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-22%
CAGR 5-Years
-5%
CAGR 10-Years
-1%
Angle PLC
LSE:AGL
Cash & Cash Equivalents
ÂŁ17.9m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Cash & Cash Equivalents
ÂŁ9.8m
CAGR 3-Years
-32%
CAGR 5-Years
-24%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cash & Cash Equivalents
$2m
CAGR 3-Years
58%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

Smith & Nephew PLC
Glance View

Market Cap
8.6B GBX
Industry
Health Care

Smith & Nephew PLC, a name synonymous with innovation in the medical technology sphere, began its journey in the late 19th century in the quaint city of Kingston upon Hull, England. This humble pharmaceutical shop evolved over time into a global leader in medical devices, driven by a commitment to improve people's quality of life through pioneering healthcare solutions. Today, the company stands as a key player in three core sectors: orthopedics, advanced wound management, and sports medicine. By focusing on these specialized areas, Smith & Nephew has set itself apart, effectively addressing the complex challenges faced by aging populations and a rising demand for minimally invasive treatments. Revenue streams pour in from their innovative products, which cater to both healthcare professionals and patients worldwide. In orthopedics, they make significant headway with implants and instruments used in hip and knee replacements, essential solutions in addressing joint deterioration and injury. Their advanced wound management division tackles issues from chronic wounds to burns, supplying dressings and delivery systems designed for optimal healing. Meanwhile, the sports medicine segment contributes by offering arthroscopy and enabling technologies, crucial for athletic injury prevention and recovery. By maintaining a strong pipeline of research and development initiatives, Smith & Nephew continues to enhance its offerings, pushing the envelope in medical technology and consequently fortifying its financial foundation.

SN Intrinsic Value
1 468.78 GBX
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Smith & Nephew PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
568m USD

Based on the financial report for Jun 29, 2024, Smith & Nephew PLC's Cash & Cash Equivalents amounts to 568m USD.

What is Smith & Nephew PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
33%

Over the last year, the Cash & Cash Equivalents growth was 199%. The average annual Cash & Cash Equivalents growth rates for Smith & Nephew PLC have been -26% over the past three years , 33% over the past five years .

Back to Top